<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006237</url>
  </required_header>
  <id_info>
    <org_study_id>ISI-001-01</org_study_id>
    <nct_id>NCT03006237</nct_id>
  </id_info>
  <brief_title>IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics</brief_title>
  <official_title>A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy Using the da Vinci® Si/Xi Surgical System With Firefly® Fluorescent Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuitive Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intuitive Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001
      Injection in Patients Undergoing Robotic Hysterectomy Using the da Vinci® Si/Xi Surgical
      System with Firefly® Fluorescent Imaging
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitor Safety Parameters (vital signs, ECG, serum chemistry and hematology, urinalysis and adverse events)</measure>
    <time_frame>14 days</time_frame>
    <description>Vital signs, 12-lead ECG, serum chemistry (CMP) and hematology (CBC), urinalysis and incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of IS-001: Cmax</measure>
    <time_frame>6 hours</time_frame>
    <description>Pharmacokinetics for IS-001 as measured by maximum serum/drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of IS-001: Tmax</measure>
    <time_frame>6 hours</time_frame>
    <description>Pharmacokinetics for IS-001 as measured by the time to maximum serum/drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of IS-001: t1/2</measure>
    <time_frame>6 hours</time_frame>
    <description>Pharmacokinetics for IS-001 as measured by terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of IS-001: AUC</measure>
    <time_frame>6 hours</time_frame>
    <description>Pharmacokinetics for IS-001 as measured by area under the serum/drug concentration time curve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hysterectomy</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>IV IS-001 drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IS-001</intervention_name>
    <description>10mg, 20mg or 40 mg IV IS-001 drug administered during surgery</description>
    <arm_group_label>IV IS-001 drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>da Vinci® Si/Xi Surgical System</intervention_name>
    <description>robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging</description>
    <arm_group_label>IV IS-001 drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is between the ages of 18 and 65.

          2. Subject is scheduled to undergo robotic hysterectomy using a da Vinci® Si/Xi surgical
             system with Firefly® fluorescent imaging.

          3. Subject is willing and able to provide informed consent.

          4. Subject is considered capable of complying with study procedures.

          5. Subject has no medical history of liver or kidney disease.

          6. Subject has no evidence of NYHA Class II-IV cardiac disease.

          7. Subject has recent (&lt; 3 months) clinical hematology (CBC) values within the acceptable
             values reference range.

          8. Subject has recent (&lt; 3 months) clinical serum chemistry (CMP) values within the
             acceptable values reference range.

        Exclusion Criteria:

          1. Subject is pregnant or nursing.

          2. Subject has a history of alcoholism.

          3. Subject has a history of drug abuse.

          4. Subject has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

          5. Subject has known human immunodeficiency virus (HIV) infection.

          6. Subject has been diagnosed with or treated for cancer in the last 2 years.

          7. Subject has a total body weight &lt; 32 kg.

          8. Subject has after 5 minutes of supine rest a diastolic blood pressure ≥100 mmHg and/or
             a systolic blood pressure ≥160 mmHg.

          9. Subject has after 5 minutes of supine rest a resting heart rate ≤35 or ≥115 bpm.

         10. Subject has any other condition or personal circumstance that, in the judgment of the
             investigator, might interfere with the collection of complete good quality data or
             represents an unacceptable safety liability.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Farnam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Urogynecology and Laser Surgery Center, Las Palmas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Las Palmas Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

